On Tuesday, Legend Biotech Corp ADR (NASDAQ: LEGN) opened higher 5.08% from the last session, before settling in for the closing price of $32.11. Price fluctuations for LEGN have ranged from $29.27 to $60.87 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 71.28% over the past five years. Company’s average yearly earnings per share was noted 18.06% at the time writing. With a float of $181.14 million, this company’s outstanding shares have now reached $183.65 million.
Let’s look at the performance matrix of the company that is accounted for 2609 employees. In terms of profitability, gross margin is 61.69%, operating margin of -37.28%, and the pretax margin is -25.21%.
Legend Biotech Corp ADR (LEGN) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Legend Biotech Corp ADR is 1.37%, while institutional ownership is 53.58%. The most recent insider transaction that took place on Mar 25 ’25, was worth 11,959. Before that another transaction happened on Mar 25 ’25, when Company’s Officer proposed sale 4,064 for $35.28, making the entire transaction worth $143,371.
Legend Biotech Corp ADR (LEGN) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 18.06% per share during the next fiscal year.
Legend Biotech Corp ADR (NASDAQ: LEGN) Trading Performance Indicators
Check out the current performance indicators for Legend Biotech Corp ADR (LEGN). In the past quarter, the stock posted a quick ratio of 4.54. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.88.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.97, a number that is poised to hit -0.21 in the next quarter and is forecasted to reach 0.52 in one year’s time.
Technical Analysis of Legend Biotech Corp ADR (LEGN)
Legend Biotech Corp ADR (NASDAQ: LEGN) saw its 5-day average volume 2.01 million, a positive change from its year-to-date volume of 1.31 million. As of the previous 9 days, the stock’s Stochastic %D was 63.66%. Additionally, its Average True Range was 1.92.
During the past 100 days, Legend Biotech Corp ADR’s (LEGN) raw stochastic average was set at 29.23%, which indicates a significant decrease from 64.50% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 59.18% in the past 14 days, which was higher than the 51.84% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $35.41, while its 200-day Moving Average is $43.04. Nevertheless, the first resistance level for the watch stands at $34.83 in the near term. At $35.92, the stock is likely to face the second major resistance level. The third major resistance level sits at $36.73. If the price goes on to break the first support level at $32.93, it is likely to go to the next support level at $32.12. Assuming the price breaks the second support level, the third support level stands at $31.03.
Legend Biotech Corp ADR (NASDAQ: LEGN) Key Stats
There are currently 183,649K shares outstanding in the company with a market cap of 6.20 billion. Presently, the company’s annual sales total 627,240 K according to its annual income of -177,030 K. Last quarter, the company’s sales amounted to 186,520 K and its income totaled 26,280 K.
